Regulatory and Safety: Obesity Drugs - Applied Clinical Trials

ADVERTISEMENT

Find Pharma Search Engine
Diabetes & Obesity Series

Safety and Regulatory Aspects of Obesity Drugs

Subscribe to RSS feed of this series


Dr. David Orloff
Executive Director of Regulatory Affairs
Medpace


Dr. Orloff discusses the current and potential future regulatory issues for obesity and diabetes drugs, how FDA and industry is moving toward levels of safety for these drug classes.

ADVERTISEMENT

ADVERTISEMENT

Untitled Document

Click here